Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
What To Know The study, published in The BMJ on January 7, summarized evidence from 37 trials involving 9,341 participants, most of whom received newer "incretin mimetic" drugs such as semaglutide (Wegovy) or tirzepatide (Mounjaro)
Its remarkable effect on appetite and weight led researchers to explore its use for non-diabetic patients struggling with obesity
All communications and medical information are handled securely within your private account in the Hi-Doctor app
Liver Protection 89-93% of patients achieved hepatic fat normalization at 48 weeks, positioning retatrutide as promising for metabolic liver disease
US$ 24.41
US$ 23.38
US$ 24.43
US$ 23.80
US$ 25.48
US$ 26.53
US$ 24.22
US$ 27.31
